Latest Period
Q4 2025
Security Snapshot
Immix Biopharma, Inc. - Common Stock, par value $0.0001 per share (IMMX) Institutional Ownership
CUSIP: 45258H106
13F Institutional Holders and Ownership History from Q4 2021 to Q1 2026
Institutions Reporting
67
Shares (Excl. Options)
24,382,712
Price
$5.23
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.
- Type / Class
- Equity / Common Stock, par value $0.0001 per share
- Symbol
- IMMX on Nasdaq
- Shares outstanding
- 53,060,943
- Price per share
- $9.11
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 24,382,712
- Total reported value
- $127,497,003
- % of total 13F portfolios
- 0%
- Share change
- +21,359,135
- Value change
- +$111,804,992
- Number of holders
- 67
- Price from insider filings
- $9.11
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- IMMX - Immix Biopharma, Inc. - Common Stock, par value $0.0001 per share is tracked under CUSIP 45258H106.
- 67 institutions reported positions in Q4 2025.
- 3 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 67 to 6 between Q4 2025 and Q1 2026.
- Reported value moved from $127,497,003 to $745,728.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 67 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 45258H106?
CUSIP 45258H106 identifies IMMX - Immix Biopharma, Inc. - Common Stock, par value $0.0001 per share in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 45258H106:
Significant Owners of Immix Biopharma, Inc. - Common Stock, par value $0.0001 per share (IMMX) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| JANUS HENDERSON GROUP PLC | 7.4% | $19,098,036 | 3,921,568 | JANUS HENDERSON GROUP PLC | 31 Dec 2025 | |||
| Saturn V Capital Management LP | 7% | $17,987,759 | 3,693,585 | Saturn V Capital Management LP | 26 Dec 2025 | |||
| MILLENNIUM MANAGEMENT LLC | 5.3% | $23,875,833 | 2,812,230 | Millennium Management LLC | 13 Mar 2026 |
As of 31 Dec 2025, 67 institutional investors reported holding 24,382,712 shares of Immix Biopharma, Inc. - Common Stock, par value $0.0001 per share (IMMX). This represents 46% of the company’s total 53,060,943 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Immix Biopharma, Inc. - Common Stock, par value $0.0001 per share (IMMX) together control 43% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| JANUS HENDERSON GROUP PLC | 7.4% | 3,921,568 | 0.01% | $20,470,585 | |
| Saturn V Capital Management LP | 5.7% | 2,999,169 | 2.9% | $15,685,654 | |
| EVENTIDE ASSET MANAGEMENT, LLC | 4.8% | 2,549,019 | 0.21% | $13,331,369 | |
| MARSHALL WACE, LLP | 3.7% | 1,978,743 | +3495% | 0.01% | $10,348,824 |
| MILLENNIUM MANAGEMENT LLC | 3.1% | 1,659,778 | 0.01% | $8,680,639 | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 2.8% | 1,500,000 | 0.01% | $7,845,000 | |
| VANGUARD GROUP INC | 2.1% | 1,095,814 | +50% | 0% | $5,731,107 |
| Logos Global Management LP | 1.9% | 1,000,000 | 0.35% | $5,230,000 | |
| Bleichroeder LP | 1.9% | 1,000,000 | +18% | 0.92% | $5,230,000 |
| Blue Owl Capital Holdings LP | 1.9% | 986,240 | 1.6% | $5,158,035 | |
| FRANKLIN RESOURCES INC | 1.8% | 980,392 | 0% | $5,127,450 | |
| AMERIPRISE FINANCIAL INC | 0.85% | 452,147 | 0% | $2,364,729 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.74% | 393,887 | +334% | 0% | $2,060,029 |
| PERCEPTIVE ADVISORS LLC | 0.64% | 338,941 | 0.03% | $1,772,661 | |
| BURKEHILL GLOBAL MANAGEMENT, LP | 0.55% | 294,118 | 0.1% | $1,538,237 | |
| RENAISSANCE TECHNOLOGIES LLC | 0.49% | 258,600 | +1103% | 0% | $1,352,478 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.46% | 246,056 | +31% | 0% | $1,287,519 |
| KVP Capital Advisors, LP | 0.43% | 230,423 | 0% | 1.2% | $1,205,112 |
| GOLDMAN SACHS GROUP INC | 0.39% | 208,370 | 0% | $1,089,775 | |
| JANE STREET GROUP, LLC | 0.31% | 167,132 | +1016% | 0% | $874,101 |
| BlackRock, Inc. | 0.25% | 130,255 | +202% | 0% | $681,233 |
| MORGAN STANLEY | 0.24% | 126,622 | +4.9% | 0% | $662,232 |
| LGT Fund Management Co Ltd. | 0.24% | 125,000 | 0.05% | $660,000 | |
| Informed Momentum Co LLC | 0.23% | 120,856 | 0.07% | $632,077 | |
| J. Goldman & Co LP | 0.22% | 118,261 | 0.02% | $618,505 |
Institutional Holders of Immix Biopharma, Inc. - Common Stock, par value $0.0001 per share (IMMX) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 81,858 | $745,728 | +$2,933 | $9.11 | 6 |
| 2025 Q4 | 24,382,712 | $127,497,003 | +$111,804,992 | $5.23 | 67 |
| 2025 Q3 | 2,765,928 | $5,781,309 | +$912,474 | $2.09 | 31 |
| 2025 Q2 | 2,262,228 | $4,682,595 | -$1,044,152 | $2.07 | 23 |
| 2025 Q1 | 2,918,442 | $4,902,496 | +$70,569 | $1.68 | 22 |
| 2024 Q4 | 2,870,949 | $6,315,600 | -$1,857,745 | $2.20 | 22 |
| 2024 Q3 | 4,094,667 | $6,102,781 | -$618,016 | $1.49 | 25 |
| 2024 Q2 | 4,429,414 | $8,774,511 | -$597,024 | $1.98 | 29 |
| 2024 Q1 | 5,090,000 | $15,715,858 | +$12,671,335 | $3.07 | 34 |
| 2023 Q4 | 783,068 | $5,326,329 | +$2,756,459 | $6.92 | 28 |
| 2023 Q3 | 405,051 | $1,385,659 | -$652,595 | $3.42 | 16 |
| 2023 Q2 | 633,819 | $1,705,059 | +$653,633 | $2.69 | 17 |
| 2023 Q1 | 400,796 | $729,846 | -$97,971 | $1.82 | 12 |
| 2022 Q4 | 440,750 | $1,011,250 | +$306,049 | $2.29 | 18 |
| 2022 Q3 | 298,959 | $406,000 | +$156,569 | $1.36 | 7 |
| 2022 Q2 | 183,385 | $475,000 | +$120,000 | $2.59 | 6 |
| 2022 Q1 | 146,485 | $352,000 | -$5,019,402 | $2.39 | 7 |
| 2021 Q4 | 1,538,439 | $5,473,200 | +$3,457,200 | $3.56 | 11 |